No human safety data exists. A theoretical concern exists around chronic HGF/c-Met pathway potentiation, as this pathway is implicated in cancer cell growth. Animal studies have not reported overt toxicity, but the total number of studies is very small and safety was not a primary endpoint.

Is it really millions of times more potent than BDNF?

This claim comes from a single study comparing synaptogenic activity in cell culture. It measures different molecular mechanisms at different concentrations. The comparison does not mean dihexa is millions of times more effective as a cognitive enhancer. It is a measure of potency for one specific effect in vitro.

Why are there so few studies?

All published dihexa research originates from a single laboratory at Washington State University (Joseph Harding lab). No independent research groups have published data. The compound has not attracted pharmaceutical development or federal research funding beyond the original lab.

Is dihexa FDA-approved?

No. Dihexa is not FDA-approved for any indication. It has no regulatory pathway, no IND application, and no clinical trials planned or underway.

What does the research show about: Dihexa is a hexapeptide analog of angiotensin IV that acts as an allosteric modu?

Dihexa is a hexapeptide analog of angiotensin IV that acts as an allosteric modulator of hepatocyte growth factor (HGF) signaling. The HGF pathway is involved in neurotrophic signaling, synaptic plasticity, and neuronal survival

What does the research show about: In animal models, dihexa has demonstrated cognitive enhancement effects at extre?

In animal models, dihexa has demonstrated cognitive enhancement effects at extremely low doses, reported to be approximately 10 million times more potent than BDNF in promoting synaptic connectivity. This potency claim is from a single research group and has not been independently replicated. The comparison measures different molecular mechanisms

What does the research show about: The compound crosses the blood-brain barrier and is active orally in rodent mode?

The compound crosses the blood-brain barrier and is active orally in rodent models, unusual properties for a peptide. Oral bioavailability and BBB penetration are advantages for potential CNS applications but do not substitute for human safety and efficacy data

What does the research show about: All 11 published studies originate from a single laboratory (Joseph Harding, Was?

All 11 published studies originate from a single laboratory (Joseph Harding, Washington State University). Single-source research without independent replication is among the most significant limitations in evaluating any compound

What does the research show about: Zero human studies of any kind: no safety, pharmacokinetic, or efficacy data in ?

Zero human studies of any kind: no safety, pharmacokinetic, or efficacy data in humans. This is one of the thinnest evidence bases for any compound with significant community interest in the PSI registry

reviewed april 2026|next review october 2026|88 physicians psi has verified|11 published studies

Dihexa

Q: What about the cancer risk?

The HGF/c-Met pathway that dihexa potentiates is a known driver of cell proliferation and is dysregulated in many cancers. c-Met is classified as a proto-oncogene. Pharmaceutical companies are developing c-Met inhibitors to treat cancer. Chronically potentiating this same pathway raises legitimate concerns that have never been investigated.

Dihexa is a modified hexapeptide derived from angiotensin IV that potentiates HGF/c-Met (hepatocyte growth factor/mesenchymal-epithelial transition factor) signaling to promote synaptogenesis, with all 11 published studies originating from a single research group and no human data of any kind.

Evidence landscape: 11 published studies

11 published items. 0 human studies and 7 animal studies. One of the thinnest evidence bases on this platform, concentrated in a single laboratory.

7 Animal
4 Reviews

All 11 published studies from one laboratory (Washington State University). No independent replication. No human data of any kind.

c-Met is a proto-oncogene. Pharmaceutical companies are developing c-Met inhibitors to treat cancer. Potentiating this pathway raises legitimate safety questions that have not been addressed.

The 'ten million times more potent than BDNF' comparison measures synaptogenic activity in cell culture. It does not mean dihexa is millions of times more effective as a cognitive enhancer.

PSI Assessment

All 11 published studies from one laboratory. No independent replication. No human data of any kind. The 'ten million times more potent than BDNF' headline has driven enormous community interest in dihexa, but the actual research base is among the thinnest in the PSI registry. The HGF/c-Met mechanism is pharmacologically interesting, the animal cognitive data is real, and the oral bioavailability is unusual for a peptide. But the c-Met receptor is classified as a proto-oncogene, and the single-source evidence base is a fundamental limitation that no amount of mechanistic elegance can overcome.

All 11 published studies from one laboratory. c-Met is a proto-oncogene. No human data of any kind exists.

The mechanism is allosteric potentiation of HGF/c-Met signaling, not direct agonism. Dihexa stabilizes the HGF/c-Met interaction, enhancing downstream Ras/MAPK and PI3K/Akt pathways that promote synaptogenesis and dendritic spine formation. The compound shows oral bioavailability and blood-brain barrier penetration in rodents, which is unusual for a peptide. The c-Met receptor is classified as a proto-oncogene, and pharmaceutical companies are developing c-Met inhibitors to treat cancer. Potentiating this pathway raises legitimate safety questions that have not been addressed in any study.

What the evidence supports

Dihexa potentiates HGF/c-Met signaling and promotes synaptogenesis in rodent models. Cognitive enhancement in aged rats is documented by the originating research group. Oral bioavailability and blood-brain barrier penetration are demonstrated in animal models.

What is not yet established

Independent replication by any laboratory outside Washington State University. Human safety, pharmacokinetics, or efficacy data of any kind. Whether the c-Met potentiation raises cancer risk with chronic use. Whether the 'ten million times more potent than BDNF' comparison has clinical relevance beyond the specific cell culture assay.

Research Evidence

The findings below cover the cognitive enhancement data, the c-Met safety concern, and the evidence base limitations.

Evidence by condition

Evidence dimensions across dihexa's investigated applications. All data comes from cell culture and animal models at one institution. No human evidence exists.

Condition	Mechanism	Animal evidence	Human evidence	Replication
Cognitive Enhancement
Neuroprotection
Synaptogenesis

Dihexa improved spatial learning and memory in aged and scopolamine-impaired rats at picomolar concentrations. The effects are attributed to HGF/c-Met-mediated synaptogenesis and dendritic spine formation.

The cognitive enhancement data in animal models is real but comes entirely from one laboratory. The 'ten million times more potent than BDNF' claim compares synaptogenic activity in cell culture across different molecular mechanisms.

The c-Met receptor that dihexa potentiates is classified as a proto-oncogene. HGF/c-Met signaling is dysregulated in many human cancers, and pharmaceutical companies are developing c-Met inhibitors as cancer treatments.

Chronically potentiating a pathway that cancer researchers are actively trying to inhibit raises a safety question that has never been addressed in any published dihexa study.

The complete evidence base consists of 11 studies from a single laboratory at Washington State University. No independent research group has published data on dihexa. No pharmaceutical company or federal agency has pursued development.

Single-source research without independent replication is among the most significant limitations in evaluating any compound. The community enthusiasm dramatically exceeds the evidence base.

0 Human|7 Animal|4 Reviews

View all 11 indexed studies

How Dihexa Works

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a modified hexapeptide derived from angiotensin IV that potentiates the HGF/c-Met receptor system.

Dihexa works on a brain growth factor pathway that helps neurons form new connections. In animal experiments it dramatically improved memory in models of cognitive impairment. No human trials exist, so whether this translates to people is entirely unknown.

For a more detailed view of the biology, here is what researchers have observed at the molecular level.

Dihexa acts as an allosteric modulator of the HGF/c-Met receptor system. Rather than activating HGF directly, it stabilizes the interaction between HGF and its receptor c-Met, amplifying downstream neurotrophic signaling through Ras/MAPK and PI3K/Akt cascades. This results in enhanced synaptogenesis, dendritic spine density, and synaptic connectivity in animal models. Dihexa was derived from the angiotensin IV receptor system (also called AT4), where that receptor was later identified as insulin-regulated aminopeptidase (IRAP).

What is Dihexa being studied for?

Researchers are studying Dihexa across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Dihexa overall. This means a compound can have human studies for one condition but only animal data for another.

Cognitive Enhancement

·Animal Studies

Animal studies show dihexa reverses cognitive deficits in aged rats and scopolamine-treated models through HGF/c-Met pathway amplification.

Limitations: No human cognitive data. All results from one laboratory. No independent replication. Rodent learning tasks have limited translational relevance.

Neuroprotection

·Animal Studies

Data from animal studies suggests dihexa may protect neurons by enhancing neurotrophic support through HGF pathway potentiation.

Limitations: Neuroprotection has not been tested in neurodegenerative disease models beyond normal age-related decline in rats. No human data.

Synaptogenesis

·Preclinical

Cell culture studies demonstrate that dihexa promotes new synaptic connections at remarkably low concentrations through HGF/c-Met stabilization.

Limitations: Synaptogenesis in cell culture does not predict functional cognitive improvement in humans.

Safety and Regulatory Status

FDA Status: Not FDA-approved. Not approved in any jurisdiction. No formal development pathway and no application for investigational use filed with any regulatory agency.

Availability: Research compound only. Not on any FDA list that limits pharmacy preparation. Has no clinical development program.

Class context: The HGF/c-Met pathway that dihexa potentiates is classified as a proto-oncogene pathway. Pharmaceutical companies are developing c-Met inhibitors for cancer treatment. Chronic potentiation of this pathway has never been evaluated for safety.

No human safety data exists. The published animal studies have not reported overt toxicity, but safety was not a primary endpoint and the total evidence base is very small. The c-Met/oncogene concern is the primary safety consideration.

Peptide Structure

Technical molecular data for researchers and clinicians.

Questions and Comparisons

Questions the evidence raises for a Dihexa discussion.

Comparison and Related Research

Dihexa is most often compared with other nootropic peptides that have substantially deeper evidence bases.

Head-to-head comparisons

Full research comparisons covering Dihexa and another peptide side by side.

Dihexa vs Semax

Dihexa has dramatic animal data but zero human evidence. Semax has Russian approval and decades of clinical use. Evidence-graded nootropic comparison.

View full comparison

Dihexa vs Cerebrolysin

Cerebrolysin has decades of clinical use in 40+ countries. Dihexa has dramatic animal data but zero human evidence. The evidence gap is enormous.

View full comparison

Related compounds

Semax Cerebrolysin Selank

Frequently Asked Questions

References

Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.

1.The original study characterizing dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) as a procognitive compound. In rat models of cognitive impairment, dihexa demonstrated potency approximately seven orders of magnitude greater than brain-derived neurotrophic factor (BDNF) in facilitating hippocampal-dependent learning and memory. The compound reversed scopolamine-induced cognitive deficits when administered orally, intracerebroventricularly, or intranasally.McCoy AT et al., 2013 in J Pharmacol Exp Ther. View on PubMed
2.This study established the mechanistic basis for dihexa's cognitive effects by demonstrating that its procognitive and synaptogenic actions depend on activation of the hepatocyte growth factor (HGF)/c-Met receptor system. In hippocampal neuronal cultures, dihexa augmented HGF-driven spinogenesis and synaptogenesis. Blocking c-Met eliminated these effects, confirming HGF/c-Met as the molecular target.Benoist CC et al., 2014 in J Pharmacol Exp Ther. View on PubMed
3.A review outlining the rationale for targeting the brain HGF/c-Met receptor system as a therapeutic strategy for Alzheimer's disease. The authors describe how angiotensin IV analogs, including dihexa, activate HGF signaling to promote synapse formation, neuronal survival, and memory consolidation. The review contextualizes dihexa within a broader framework of neurotrophic approaches to neurodegeneration.Wright JW, Harding JW, 2015 in J Alzheimers Dis. View on PubMed
4.This preclinical study described the rational design and development of metabolically stable angiotensin IV analogs, including the compound that became dihexa. The paper demonstrated that these analogs augment HGF-dependent signaling through the c-Met receptor, promoting scattering and proliferation in cell-based assays. The work provided the structure-activity relationships that guided dihexa's development as a procognitive agent.Kawas LH et al., 2012 in J Pharmacol Exp Ther. View on PubMed

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.